Intestinal perforation after intravitreal low dose ranibizumab injection for the treatment of type 1 retinopathy of prematurity: A case report.
Turkay RzayevHande CelikerAslan AykutKivilcim CeritAli KoyuncuerSafak GucyetmezHulya OzdemirAsli MemisogluHulya BilgenEren OzekPublished in: European journal of ophthalmology (2022)
The risk of GIS perforation should be taken into consideration during the application of intravitreal vascular endothelial growth factor antagonist agents, especially in newborns with previous GIS surgery and a history of NEC, and these patients should be carefully monitored for GIS complications.
Keyphrases
- vascular endothelial growth factor
- low dose
- end stage renal disease
- endothelial cells
- diabetic retinopathy
- age related macular degeneration
- ejection fraction
- minimally invasive
- chronic kidney disease
- newly diagnosed
- pregnant women
- prognostic factors
- peritoneal dialysis
- high dose
- risk factors
- coronary artery disease
- acute coronary syndrome
- gestational age
- preterm infants
- percutaneous coronary intervention
- smoking cessation